Literature DB >> 11330434

Uric acid nephrolithiasis associated with interferon and ribavirin treatment of hepatitis C.

R J Fontana1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11330434     DOI： 10.1023/a:1010789425975

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  9 in total

1.  Hemolytic anemia secondary to alpha-interferon treatment in a patient with chronic C hepatitis.

Authors:  C de-la-Serna-Higuera; R Bárcena-Marugán; E Sanz-de-Villalobos
Journal:  J Clin Gastroenterol       Date:  1999-06       Impact factor: 3.062

2.  Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

Authors:  H C Bodenheimer; K L Lindsay; G L Davis; J H Lewis; S N Thung; L B Seeff
Journal:  Hepatology       Date:  1997-08       Impact factor: 17.425

3.  Ribavirin pharmacodynamics in high-risk patients for acquired immunodeficiency syndrome.

Authors:  R B Roberts; O L Laskin; J Laurence; D Scavuzzo; H W Murray; Y T Kim; J D Connor
Journal:  Clin Pharmacol Ther       Date:  1987-10       Impact factor: 6.875

Review 4.  National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C.

Authors: 
Journal:  Hepatology       Date:  1997-09       Impact factor: 17.425

5.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

Authors:  T Poynard; P Marcellin; S S Lee; C Niederau; G S Minuk; G Ideo; V Bain; J Heathcote; S Zeuzem; C Trepo; J Albrecht
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

6.  A pilot study of ribavirin therapy for chronic hepatitis C.

Authors:  A M Di Bisceglie; M Shindo; T L Fong; M W Fried; M G Swain; N V Bergasa; C A Axiotis; J G Waggoner; Y Park; J H Hoofnagle
Journal:  Hepatology       Date:  1992-09       Impact factor: 17.425

7.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

8.  Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.

Authors:  G L Davis; R Esteban-Mur; V Rustgi; J Hoefs; S C Gordon; C Trepo; M L Shiffman; S Zeuzem; A Craxi; M H Ling; J Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

9.  Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.

Authors:  A M Di Bisceglie; H S Conjeevaram; M W Fried; R Sallie; Y Park; C Yurdaydin; M Swain; D E Kleiner; K Mahaney; J H Hoofnagle
Journal:  Ann Intern Med       Date:  1995-12-15       Impact factor: 25.391
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.